"With increasing numbers of patients with type 2 diabetes in trials for SGLT-2 inhibitors or GLP-1 receptor agonists who were also on the other drug class, we've done large, stratified analyses that suggest no treatment-effect modification" when people received agents from both drug classes, M...
ESC backs SGLT2 inhibitor plus GLP-1 in diabetes with high CVD riskZoler, Mitchel L.Cardiology News
美国糖尿病协会出版的指南指出，对于每日使用基础胰岛素多于0.5 IU/kg但HbA1c不达标的患者，可以选择在治疗方案中加入每日一次餐前胰岛素或GLP-1RA【4】。那么，具有相似优势的SGLT2抑制剂，是否也可以和餐前胰岛素“平起平坐”呢？对于每天注射多次胰岛素的患者，将餐前胰岛素转成GLP-1RA或SGLT2抑制剂是否可行有效...
苏州华测生物技术有限公司顺利通过国家药监局(NMPA)药物GLP定期检查 MC4R靶点全球研发格局分析 华人之光:克里唑替尼的研发历程 生物类似药研发相关问题问与答 新型抗侵袭性真菌感染药物研究进展 首款乳腺癌PI3K抑制剂在美上市,诺华开启乳腺癌分子分型新时代 全球糖尿病患者福音!首款SGLT1/SGLT2双效口服降糖药...
如今,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂被广泛应用于治疗2型糖尿病。然而有研究显示,与胰高血糖素样肽1(GLP-1)受体激动剂相比,SGLT2抑制剂的下肢截肢和糖尿病酮症酸中毒的风险高出一倍。 为了评估SGLT2抑制剂的安全性,研究人员对2013年7月至2016年12月瑞典和丹麦SGLT2抑制剂患者应用数据进行了分析。研究纳入...
On the basis of complementary mechanisms of action and metabolic effects, the combination of SGLT2 inhibition plus GLP-1-RA therapy is an attractive option to enhance weight loss and reduce major adverse cardiovascular events in selected patients. Data on combination therapy have, however, been spar...
Few studies explored the effect of the combination of glucose sodium-cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on the incidence of cardiovascular events in patients with type 2 diabetes (T2D) and acute myocardial infarction (AMI). Methods We re...
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have shown promising cardiorenal benefits, especially in diabetic patients with severe kidney disease, heart failure (HF), or a history of myocardial infarction (MI). Drugs like empagliflozin, canaglifl
进一步的研究发现,sotagliflozin可通过抑制SGLT1降低从胃肠道进入血液的葡萄糖量,将葡萄糖转运至盲肠,提高餐后GLP-1、酪酪肽(PYY)和胃肠激素释放,并可通过抑制SGLT2增强尿糖排泄来控制患者血糖水平[11,12]。与其他选择性SGLT2抑制剂相比,sotagliflozin在餐后血糖、糖化血红蛋白(HbA1C)控制方面作用更佳,且不出现腹泻...
Abstract 4147387: Outcomes of Heart Failure with Preserved Ejection Fraction with GLP1RA plus SGLT2i vs SGLT2i alone: A Propensity-Matched Nationwide Cohor... Introduction:Metabolic pharmacotherapies [Glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter type 2 inhibitors...